Compass Therapeutics: A Promising, But Shrinking, Window Of Opportunity

Compass Therapeutics faces a major setback after tovecimig failed to show an overall survival benefit in biliary tract cancer. CMPX plans to pursue a BLA submission for tovecimig despite FDA guidance recommending a new survival-focused trial.

Financial runway extends into 2028, but delays or regulatory setbacks could force CMPX to raise capital from a weakened position. While market sentiment is highly pessimistic, I see a rare, high-risk 'Buy' opportunity if investors exercise strict discipline.